AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc.   today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have...

Related Keywords

United States ,American ,Robert Edwards ,Thomask Equels ,Exchange Commission ,Department Of Obstetrics ,Immunotech Inc ,Facebook ,Gynecologic Oncology Research At Magee Womens Hospital ,University Of Pittsburgh Medical Center ,Gynecology Reproductive Sciences ,Linkedin ,Immune Checkpoint Blockade ,Recurrent Ovarian ,Pittsburgh Medical Center ,Objective Response Rate ,Clinical Benefit Rate ,Progression Free Survival ,Reproductive Sciences ,Gynecologic Oncology Research ,Magee Womens Hospital ,Executive Officer Thomas ,Private Securities Litigation Reform Act ,Markets ,